Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 3/20 | 0.46 |
| ▸ | CES2 | O00748 | 2/20 | 0.43 |
| ▸ | TACR1 | P25103 | 7/20 | 0.40 |
| ▸ | PNMT | P11086 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL435108 | 1.00 | PDE2A (0.46) | PDE2ACES2TACR1PNMTIDO1 | |
| SCHEMBL99424 | 1.00 | PDE2A (0.46) | PDE2ACES2TACR1PNMTIDO1 | |
| SCHEMBL9386794 | 0.96 | PDE2A (0.43) | PDE2ACES2TACR1PNMTIDO1 | |
| SCHEMBL23895404 | 0.92 | PDE2A (0.41) | PDE2ACES2TACR1PNMTIDO1 | |
| SCHEMBL7250729 | 0.88 | PDE2A (0.39) | PDE2ACES2TACR1 | |
| SCHEMBL5199897 | 0.87 | PDE2A (0.41) | PDE2ACES2TACR1PNMTMAPT | |
| SCHEMBL1295024 | 0.87 | PDE2A (0.41) | PDE2ACES2TACR1PNMTPTPN5 | |
| SCHEMBL12118738 | 0.87 | PDE2A (0.41) | PDE2ACES2TACR1PNMTMAPT | |
| SCHEMBL31560879 | 0.87 | PDE2A (0.41) | PDE2ACES2TACR1PNMTPTPN5 | |
| SCHEMBL15216810 | 0.87 | PDE2A (0.41) | PDE2ACES2TACR1PNMTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 259 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120157629-A | Synthesis process of morpholone derivative | 北京颖诺凯胜科技有限公司 | 2025-06-17 | — | — | CN | claimed |
| CN-119874524-A | Fluoroaryl compound, preparation method, packaging ink composition comprising fluoroaryl compound, use method and application of fluoroaryl compound | 西安思摩威新材料有限公司 | 2025-04-25 | — | — | CN | claimed |
| CN-106399398-B | Biological preparation method of (R) -3, 5-bis (trifluoromethyl) phenethyl alcohol | 上海医药工业研究院 | 2024-07-09 | — | — | CN | claimed |
| CN-114405437-B | Photoelectrocatalysis device and application thereof | 太原师范学院 | 2023-10-27 | — | — | CN | claimed |
| CN-109516964-B | Preparation method of aprepitant intermediate | 鲁南制药集团股份有限公司 | 2022-05-31 | — | — | CN | claimed |
| CN-112666279-B | Detection method for purity and impurities of aprepitant intermediate | 中山奕安泰医药科技有限公司 | 2022-05-20 | — | — | CN | claimed |
| CN-114405437-A | Photoelectrocatalysis device and application thereof | 太原师范学院 | 2022-04-29 | — | — | CN | claimed |
| CN-113388627-A | Reductase LX05 gene, genetic engineering bacterium containing gene and application of gene | 湖南科技大学 | 2021-09-14 | — | — | CN | claimed |
| CN-112666279-A | Detection method for purity of aprepitant intermediate and impurities of aprepitant intermediate | 中山奕安泰医药科技有限公司 | 2021-04-16 | — | — | CN | claimed |
| CN-104513837-B | Chiral synthesis method of (R) -1- [3, 5-bis (trifluoromethyl) phenyl ] ethanol | 鲁南制药集团股份有限公司 | 2020-01-24 | — | — | CN | claimed |
| CN-103497911-B | Application of Chryseobacterium sp. and carbonyl reductase thereof in production of aprepitant chiral intermediate | CHENGDU INST BIOLOGY CAS | 2015-03-25 | — | — | CN | claimed |
| WO-2014150633-A1 | IMMOBILIZED KETOREDUCTASES AND PROCESS FOR MAKING AND USING IMMOBILIZED KETOREDUCTASE | MERCK SHARP & DOHME CORP. (US) | 2014-09-25 | — | — | WO | claimed |
| US-20130190540-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE 1-BROMO-1-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]ETHANE | KOWA COMPANY, LTD. (JP) | 2013-07-25 | — | — | US | claimed |
| EP-2597079-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 1-BROMO-1-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]ETHANE | Kowa Company Ltd. (JP) | 2013-05-29 | — | — | EP | claimed |
| CN-102382780-B | Microbacterium oxydans and method for preparing chiral bis(trifluoromethyl) phenyl ethanol by using same | CHENGDU INST BIOLOGY CAS | 2013-02-13 | — | — | CN | claimed |
| CN-102382780-A | Microbacterium oxydans and method for preparing chiral bis(trifluoromethyl) phenyl ethanol by using same | CHENGDU INST BIOLOGY CAS | 2012-03-21 | — | — | CN | claimed |
| US-20030153760-A1 | Treating 1-(3,5- bis(trifluoromethyl)phenyl)ethan-1-one with bis((pentamethylcyclopentadienyl)rhodium chloride) and (S,R)-cis-1-amino-2-hydroxy-indane in the presence of isopropanol | MERCK & CO., INC. | 2003-08-14 | — | — | US | claimed |
| US-6504066-B1 | Reduction of halogen containing carbocyclic ketones, to form chemical intermediates which are substance-P receptor antagonists useful as antiinflammatory and antiemetic agents and for treatment of psychological disorders | MERCK & CO. INC. | 2003-01-07 | — | — | US | claimed |
| US-6469164-B2 | 2-HYDROXY GROUP OF 4-BENZYL-2-HYDROXY-1,4-OXAZIN-3-ONE IS ACTIVATED WITH 1-(3,5-BIS(TRIFLUOROMETHYL)-PHENYL) ETHAN-1-OL IN PRESENCE OF LEWIS ACID, CRYSTALLIZATION OF DRIVEN EPIMERIZATION OF ANOMERIC CENTER WITH A BASE | MERCK & CO., INC. | 2002-10-22 | — | — | US | claimed |
| US-20020052493-A1 | Process for the synthesis of (2R, 2-alpha-R) -4-benzyl-2-[1- (3,5-bis (trifluoromethyl) phenyl) ethoxy] -1,4-oxazine-3-one | MERCK SHARP & DOHME CORP. | 2002-05-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052493-A1 | Process for the synthesis of (2R, 2-alpha-R) -4-benzyl-2-[1- (3,5-bis (trifluoromethyl) phenyl) ethoxy] -1,4-oxazine-3-one | CYP4B1, CBR1, CYP4Z1 | PDE2A 1176/4885CES2 391/4885TACR1 591/4885 |
| US-20130190540-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE 1-BROMO-1-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]ETHANE | RPP30, BRPF1, ALK | PDE2A 4036/4885CES2 1977/4885TACR1 747/4885 |
| US-20030153760-A1 | Treating 1-(3,5- bis(trifluoromethyl)phenyl)ethan-1-one with bis((pentamethylcyclopentadienyl)rhodium chloride) and (S,R)-cis-1-amino-2-hydroxy-indane in the presence of isopropanol | HTR1D, SIGMAR1, HTR1A | PDE2A 4401/4885CES2 772/4885TACR1 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.